Celltrion is making further strides on one of the significant ‘next wave’ biosimilar opportunities, kicking off a global Phase III trial for biosimilar Xolair (omalizumab) following approval for the firm’s investigational new drug application from Korea’s Ministry of Food and Drug Safety.
Celltrion Takes Big Step On Xolair Biosimilar Journey
Phase I Trial For Omalizumab Candidate Began Last Year
Biosimilars major Celltrion has announced further progress on its biosimilar Xolair candidate, as it faces off against the likes of Glenmark to introduce global competition to Genentech/Novartis’ blockbuster cardiovascular biologic.
